Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 48
Filtrar
1.
Clin Res Hepatol Gastroenterol ; 48(2): 102285, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38246488

RESUMEN

BACKGROUND: Data on post-colonoscopy colorectal cancers (PCCRCs) after fecal occult blood test (FOBT)-positive colonoscopies is scarce (guaiac-based (gFOBT) or fecal immunochemical test (FIT)). AIMS: Evaluate the prevalence and characteristics of PCCRCs in the French gFOBT CRC screening program. METHODS: Retrospective population-based cohort study of all gFOBT-positive colonoscopies performed among individuals aged 50-74 between 2003 and 2014 within the CRC screening program organized in the Haut-Rhin (Alsace, France). The main outcome was PCCRC-3y rate. Adenoma detection rates (ADRs) calculated on gFOBT-positive colonoscopies were compared to those calculated on FIT-positive colonoscopies performed by the same gastroenterologists. RESULTS: Overall, 9106 gFOBT-positive colonoscopies performed by 36 gastroenterologists were included. Sixteen PCCRC-3y and 31 PCCRC-5y were diagnosed (68.8 % and 58.1 % were true interval PCCRCs respectively). The unadjusted PCCRC-3y rate was 2.4 % [95 % confidence interval (CI) 1.4 %-3.9 %]. The risk for PCCRC-5y was significantly higher when the gastroenterologist's ADR was <35 % compared to ≥35 % (HR 2.17 [95 %CI 1.19-3.93]). The mean absolute difference for ADR between gFOBT- and FIT-positive colonoscopies was 16.3 % in favor of FIT-positive colonoscopies. CONCLUSION: PCCRC-3y prevalence was low, estimated at 2.4 %. We suggest that the minimum standard for ADR in gFOBT- and FIT-positive colonoscopies should be set at 35 % and 50 % to 55 % respectively, in the French screening program.


Asunto(s)
Neoplasias Colorrectales , Guayaco , Humanos , Estudios de Cohortes , Estudios Retrospectivos , Tamizaje Masivo , Sangre Oculta , Neoplasias Colorrectales/diagnóstico , Neoplasias Colorrectales/epidemiología , Colonoscopía , Detección Precoz del Cáncer
2.
Pancreatology ; 23(1): 48-56, 2023 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-36517351

RESUMEN

BACKGROUND: PRSS1 and PRSS2 constitute the only functional copies of a tandemly-arranged five-trypsinogen-gene cluster (i.e., PRSS1, PRSS3P1, PRSS3P2, TRY7 and PRSS2) on chromosome 7q35. Variants in PRSS1 and PRSS2, including missense and copy number variants (CNVs), have been reported to predispose to or protect against chronic pancreatitis (CP). We wondered whether a common trypsinogen pseudogene deletion CNV (that removes two of the three trypsinogen pseudogenes, PRSS3P2 and TRY7) might be associated with CP causation/predisposition. METHODS: We analyzed the common PRSS3P2 and TRY7 deletion CNV in a total of 1536 CP patients and 3506 controls from France, Germany, India and Japan by means of quantitative fluorescent multiplex polymerase chain reaction. RESULTS: We demonstrated that the deletion CNV variant was associated with a protective effect against CP in the French, German and Japanese cohorts whilst a trend toward the same association was noted in the Indian cohort. Meta-analysis under a dominant model yielded a pooled odds ratio (OR) of 0.68 (95% confidence interval (CI) 0.52-0.89; p = 0.005) whereas an allele-based meta-analysis yielded a pooled OR of 0.84 (95% CI 0.77-0.92; p = 0.0001). This protective effect is explicable by reference to the recent finding that the still functional PRSS3P2/TRY7 pseudogene enhancers upregulate pancreatic PRSS2 expression. CONCLUSIONS: The common PRSS3P2 and TRY7 deletion CNV was associated with a reduced risk for CP. This finding provides additional support for the emerging view that dysregulated PRSS2 expression represents a discrete mechanism underlying CP predisposition or protection.


Asunto(s)
Pancreatitis Crónica , Tripsinógeno , Humanos , Alelos , Variaciones en el Número de Copia de ADN/genética , Predisposición Genética a la Enfermedad , Genotipo , Mutación , Pancreatitis Crónica/genética , Tripsina/genética , Tripsinógeno/genética
3.
Therapie ; 78(1): 131-143, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36572627

RESUMEN

In 2018, the "Ateliers de Giens" (Giens Workshops) devoted a workshop to artificial intelligence (AI) and led its experts to confirm the potential contribution and theoretical benefit of AI in clinical research, pharmacovigilance, and in improving the efficiency of care. The 2022 workshop is a continuation of this reflection on AI and intelligent automation (IA) by focusing on its contribution to pharmacovigilance and the applications and tasks could be optimized to preserve and strengthen medical and pharmacological expertise in pharmacovigilance. The evolution of pharmacovigilance work is characterized by many tasks with low added value, a growing volume of pharmacovigilance reporting of suspected side effects, and a scarcity of medical staff with expertise in clinical pharmacology and pharmacovigilance and human resources to support this growing need. Together, these parameters contribute to an embolization of the pharmacovigilance system at risk of missing its primary mission: to identify and characterize a risk or even a health alert on a drug. The participants of the workshop (representatives of the Regional Pharmacovigilance Centres (CRPV), the French National Agency for Safety of Medicinal Products (ANSM), patients, the pharmaceutical industry, or start-ups working in the development of AI in the field of medicine) shared their experiences, their pilot projects and their expectations on the expected potential, theoretical or proven, AI and IA. This work has made it possible to identify the needs and challenges that AI or IA represent, in the current or future modes of organization of pharmacovigilance activities. This approach led to the development of a SWOT matrix (strengths, weaknesses, opportunities, threats), a basis for reflection to identify critical points and consider four main recommendations: (1) preserve and develop business expertise in pharmacovigilance (including research and development in methods) with the integration of new technologies; (2) improve the quality of pharmacovigilance reports; (3) adapt technical and regulatory means; (4) implement a development strategy for AI and IA tools at the service of expertise.


Asunto(s)
Inteligencia Artificial , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Humanos , Automatización , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Farmacovigilancia , Industria Farmacéutica
6.
Rev Prat ; 72(8): 889-897, 2022 Oct.
Artículo en Francés | MEDLINE | ID: mdl-36511994

RESUMEN

RISK AND PROTECTIVE FACTORS FOR COLORECTAL CANCER Behaviour and environment play a more important role than heredity in colorectal carcinogenesis. The proportion of colorectal cancers (CRCs) attributable to occupational exposure, pollution or poor socio- economic status is low. The risk levels on which the French CRC screening recommendations are based are obsolete and need to be updated. An individual with one or two non-advanced adenomas resected at colonoscopy is at low risk of CRC. Only a first-degree family history of CRC in one parent before age 50 or in two parents at any age confers a significant increased risk. Certain diseases or situations that are sources of an increased risk of CRC were not previously considered: cystic fibrosis, radiotherapy and paediatric cancer survivors. New inherited predisposition syndromes associated with a very high risk of CRC have been described in addition to Lynch syndrome and familial adenomatous polyposis: MUTYH-associated polyposis, constitutional MMR deficiency, Lynch-like, PPAP and X syndromes. Half of all CRCs are related to modifiable risk factors associated with westernized lifestyle such as physical inactivity, junk food and obesity. There is nothing specific about dietary recommendations for the primary prevention of CRC: physical activity, limitation of red and processed meat, increase in dietary fibre and dairy products, limitation of alcohol and avoidance of tobacco. Finally, it is premature to use aspirin in primary prevention of CRC outside of Lynch syndrome and associated significant cardiovascular risk.


FACTEURS DE RISQUE ET DE PROTECTION DU CANCER COLORECTAL Comportement et environnement jouent un rôle plus important que l'hérédité dans la carcinogenèse colorectale. La part des cancers colorectaux (CCR) attribuable à une exposition professionnelle, à la pollution ou à un statut socio-économique défavorable est faible. Les niveaux de risque sur lesquels reposent les recommandations françaises de dépistage du CCR sont obsolètes et doivent être actualisés. Un individu ayant un ou deux adénomes non avancés réséqués lors d'une coloscopie est à risque faible de CCR. Seuls les antécédents familiaux au 1er degré de CCR chez un parent avant 50 ans ou chez deux parents quel que soit l'âge confèrent un surrisque significatif. Certaines maladies ou situations sources d'un sur-risque de CCR n'étaient pas prises en compte précédemment : mucoviscidose, radiothérapie et survivant de cancer pédiatrique. De nouveaux syndromes de prédisposition héréditaire associés à un risque très élevé de CCR ont été décrits en sus du syndrome de Lynch et de la polypose adénomateuse familiale : polypose associée à MUTYH, syndromes de déficience constitutionnelle du système MMR, Lynch-like, PPAP et X. La moitié des CCR sont liés à des facteurs de risque modifiables associés au mode de vie occidental tels que sédentarité, malbouffe et obésité. Les recommandations hygiéno-diététiques destinées à la prévention primaire du CCR n'ont rien de spécifique : activité physique, limitation des viandes rouges et charcuteries, augmentation des fibres alimentaires et produits laitiers, limitation de l'alcool et éviction du tabac. Enfin, il est prématuré d'utiliser l'aspirine en prévention primaire du CCR en dehors du syndrome de Lynch et d'un risque cardiovasculaire significatif associé.


Asunto(s)
Poliposis Adenomatosa del Colon , Neoplasias Colorrectales Hereditarias sin Poliposis , Neoplasias Colorrectales , Niño , Humanos , Persona de Mediana Edad , Poliposis Adenomatosa del Colon/diagnóstico , Poliposis Adenomatosa del Colon/genética , Poliposis Adenomatosa del Colon/prevención & control , Colonoscopía , Neoplasias Colorrectales/diagnóstico , Neoplasias Colorrectales/epidemiología , Neoplasias Colorrectales/etiología , Predisposición Genética a la Enfermedad , Factores Protectores , Factores de Riesgo
7.
Endosc Int Open ; 10(9): E1208-E1217, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-36118642

RESUMEN

Background and study aims Neoplasia-related indicators, such as adenoma detection rate (ADR), are a priority in the quality improvement process for colonoscopy. Our aim was to assess and compare different detection and characterization indicators in fecal immunochemical test (FIT)-positive colonoscopies, to determine associated factors, and to propose benchmarks. Patients and methods Retrospective analysis of prospectively collected data from all colonoscopies performed between 2015 and 2019 after a positive quantitative FIT in the population-based colorectal cancer screening program conducted in Alsace, part of the French national program. Detection indicators included ADR, mean number of adenomas per colonoscopy, and proximal serrated lesion (SL) detection rate. Characterization indicators included rate of non-neoplastic polyp (NNP) detection. Results Overall, 13,067 FIT-positive colonoscopies were evaluated, performed by 80 community gastroenterologists. The overall ADR was 57.6 %, and a 10 µg/g increase in fecal hemoglobin concentration was significantly associated with higher ADR (odds ratio [95 % confidence interval] = 1.02 [1.02-1.03]). Endoscopists whose ADR was ≥ 55 % were high detectors for all neoplasia, including proximal SLs and number of adenomas. The rate of detection of NNPs was 39.5 % in highest detectors (ADR > 70 %), significantly higher than in lower detectors (21.4 %) ( P  < 0.001). There was a strong correlation between detection and characterization indicators, e. g. between rates of detection of proximal SLs and NNPs (Pearson = 0.73; P  < 0.01). Conclusions A single indicator, ADR, is enough to assess endoscopist performance for both detection and characterization in routine practice provided the minimum target standard is raised and a maximum standard is added: 55 % and 70 % for FIT-positive colonoscopies, respectively.

9.
Therapie ; 77(1): 79-88, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35078658

RESUMEN

In the code of public health, misuse is defined as intentional and inappropriate use of a medicine or product, which is not in accordance with the terms of the marketing authorisation or the registration as well as with good practice recommendations. Very often this involves an individual or the interaction of several individuals including the patient, his/her carers, prescriber(s) and/or dispensers. Misuse is common; it is the source of medicinal adverse effects for which a significant part is avoidable. Medicines initially prescribed or dispensed in the context of their marketing authorization (MA) can also be the subject of primary dependency and misappropriation. Companies which develop medicines nationally make declarations to the ANSM (French National Agency for the Safety of Medicines and Health Products) and implement measures to limit non-compliant use of their products. Recently, the coronavirus disease-2019 (COVID-19) pandemic has highlighted the influence and societal impact of drug misuse. The finding of the existence of systemic misuse, the impossibility of proposing simple solutions leads us to propose two main areas for improved information and the training of users and health professionals in medicines in the context of multi-faceted interventions: prevention of misuse on the one hand and its identification and treatment on the other hand.


Asunto(s)
COVID-19 , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Femenino , Humanos , Masculino , Salud Pública , SARS-CoV-2
10.
J Med Screen ; 29(2): 84-91, 2022 06.
Artículo en Inglés | MEDLINE | ID: mdl-34866481

RESUMEN

OBJECTIVE: To evaluate the quality of colonoscopies performed after a positive faecal immunochemical test in the French colorectal cancer screening programme. METHODS: Retrospective analysis of all colonoscopies performed between 2015 and 2019 after a positive quantitative faecal immunochemical test in the population-based colorectal cancer screening programme organised in Alsace, part of the French programme. The following indicators were evaluated: annual colonoscopy volume, caecal intubation rate, adenoma detection rate, proximal serrated lesion detection rate and proportion of patients referred directly to surgery for benign polyp management. Endoscopists who performed <30 faecal immunochemical test positive colonoscopies were non-assessable. RESULTS: Overall, 13,455 faecal immunochemical test-positive colonoscopies performed by 116 community gastroenterologists were included, 13,067 of them by 80 assessable endoscopists. The overall caecal intubation, adenoma detection and proximal serrated lesion detection rates were 97.9%, 57.6% and 7.6%, respectively. They were <90%, <45% and <1% for 1.3%, 12.5% and 6.3% of the endoscopists, respectively. Overall, 1028 (7.9%) individuals were examined by 13 low-performing endoscopists and 328 (2.4%) individuals by 33 low-volume non-assessable endoscopists. Among 9133 individuals harbouring polyps, 155 (1.7%) had unwarranted surgery for a benign polyp. Overall, 1487 individuals (11.1%; 95% confidence interval 10.5-11.6) were not given the best possible chances, whereas 5545 individuals (41.2%; 95% confidence interval 40.4-42.0) were offered the best possible chances by 37 endoscopists. CONCLUSIONS: At programme level, the key performance indicators evaluated largely exceeded the target standards. At individual level, at least one in nine individuals was not given the best possible chances during faecal immunochemical test-positive colonoscopies by a minority of poor-performing and/or low-volume endoscopists.


Asunto(s)
Adenoma , Neoplasias Colorrectales , Adenoma/diagnóstico , Colonoscopía , Neoplasias Colorrectales/diagnóstico , Detección Precoz del Cáncer , Humanos , Tamizaje Masivo , Estudios Retrospectivos
11.
Endosc Int Open ; 9(11): E1649-E1657, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34790527

RESUMEN

Background and study aims The aim of this study was to analyze presentation, management, and outcomes of large polyps (LPs; ≥ 20 mm) detected in a colorectal cancer (CRC) screening program using a quantitative fecal immunochemical test (FIT). Patients and methods This was a retrospective community- and population-based observational study of all LPs detected in patients aged 50 to 74 years between 2015 and 2019 during FIT-positive colonoscopies within the screening program organized in Alsace (France). Results Among 13,633 FIT-positive colonoscopies, 1256 LPs (8.5 % malignant and 51.8 % nonpedunculated) were detected by 102 community gastroenterologists in 1164 patients (one in 12 colonoscopies). The sensitivity of optical diagnosis of malignancy was 54 % for nonpedunculated and 27 % for pedunculated T1 CRCs. The endoscopic resection rate was 82.7 % (95 % confidence interval [CI] 80.3-84.9) for benign LPs (70.2 % [95 % CI 66.4-74.1]) nonpedunculated, 95.2 % [95 % CI 93.4-97.1] pedunculated), varying from 0 to 100 % depending on the endoscopist. It was correlated with cecal intubation (Pearson r  = 0.49, P  < 0.01) and adenoma detection rates ( r  = 0.25, P  = 0.01). Most endoscopists did not refer patients to more experienced endoscopists, and as a result, 60 % to 90 % of 183 surgeries for benign LPs were unwarranted. Endoscopic resection was curative for 4.3 % (95 % CI 0.9-12.0) of nonpedunculated and 37.8 % (95 % CI 22.5-55.2) of pedunculated T1 CRCs. Overall, 22 endoscopic submucosal dissections had to be performed to avoid one surgery. Conclusions Compared with current recommendations, there is tremendous room for improvement in community endoscopy practices in the diagnosis and management of LPs. Detection and polypectomy competencies are correlated and highly variable among endoscopists. Endoscopic resection is curative for 83 % of benign LPs and 16 % of T1 CRCs.

13.
Rev Prat ; 71(5): 543-550, 2021 May.
Artículo en Francés | MEDLINE | ID: mdl-34553536

RESUMEN

"In current practice, what is the best test to detect the presence of blood in faeces? Testing for the presence of blood in faeces is still widely performed in France, although the uptake in the national colorectal cancer screening programme is less than desirable, as is use in routine practice to guide diagnosis when patients present with gastrointestinal or general symptoms. Guaiac-based tests (Hemoccult) are obsolete and have been replaced by faecal immunochemical tests (FITs), both quantitative (OC-Sensor), currently reserved for the screening programme, and qualitative, performed by all medical laboratories. However, qualitative FITs should be abandoned: their visual reading is subjective, their positivity rate is highly variable, around 50%, and their diagnostic sensitivity for colorectal cancer has not been well determined. In contrast, quantitative FITs are reliable and their performance has been well evaluated. Several neighbouring countries use these tests in general practice to assess the risk of colorectal cancer in symptomatic patients and to determine the indication for colonoscopy. In this context, the decision thresholds are very different from those of organised screening: a faecal haemoglobin concentration below 4-10 µg/g is associated with a very low risk of cancer, a concentration above 4-10 µg/g should be investigated by colonoscopy, and a concentration above 150 µg/g requires an urgent colonoscopy."


"En pratique courante, quel est le meilleur test pour rechercher du sang dans les selles ? La recherche de sang dans les selles, malgré son caractère quelque peu désuet, est, à juste titre, encore très prescrite en France, insuffisamment dans le programme national de dépistage organisé du cancer colorectal et en pratique courante pour guider une conduite diagnostique en cas de symptômes digestifs ou généraux. Les tests au gaïac (Hemoccult), obsolètes, ont été remplacés par des tests immunochimiques, quantitatifs (OC-Sensor) réservés au programme de dépistage, et qualitatifs réalisés par tous les laboratoires de biologie médicale. Pourtant les tests qualitatifs sont obsolètes et devraient être abandonnés : leur lecture est subjective, leur taux de positivité très variable, proche de 50 %, et leur sensibilité diagnostique pour le cancer colorectal non évaluée. Au contraire, les tests quantitatifs sont fiables et leurs performances parfaitement évaluées. Plusieurs pays voisins utilisent ces tests en médecine générale pour évaluer le risque de cancer colorectal chez les patients symptomatiques et poser l'indication d'une coloscopie. Dans ce contexte, les seuils décisionnels sont très différents de ceux du dépistage organisé : un taux d'hémoglobine fécale inférieur à 4-10 µg/g de selles est associé à un risque infime de cancer, un taux supérieur à 4-10 µg/g doit être exploré par coloscopie, et un taux supérieur à 150 µg/g relève d'une coloscopie urgente."


Asunto(s)
Neoplasias Colorrectales , Sangre Oculta , Colonoscopía , Neoplasias Colorrectales/diagnóstico , Detección Precoz del Cáncer , Heces , Humanos , Tamizaje Masivo , Sensibilidad y Especificidad
15.
Endosc Int Open ; 9(2): E224-E232, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33553585

RESUMEN

Background and study aims The aim of this study was to assess adverse events (AEs) associated with colonoscopy in the French colorectal cancer screening program with fecal occult blood test (FOBT). Patients and methods A retrospective cohort study was performed of all colonoscopies performed from 2015 to 2018 for a positive fecal immunochemical test (FIT) in patients aged 50 to 74 years within the screening program in progress in Alsace, part of the French program. AEs were recorded through prospective voluntary reporting by community gastroenterologists and retrospective postal surveys addressed to individuals screened. They were compared with those recorded in the previous program following colonoscopies performed from 2003 to 2014 for a positive guaiac-based FOBT (gFOBT). Results Of 9576 colonoscopies performed for a positive FIT, 6194 (64.7 %) were therapeutic. Overall, 180 AEs were recorded (18.8 ‰, 95 % CI 16.1-21.5), 114 of them (11.9 ‰, 95 % CI 9.7-14.1) requiring hospitalization, 55 (5.7‰, 95 % CI 4.2-7.3) hospitalization > 24 hours, and eight (0.8 ‰, 95 % CI 0.3-1.4) surgery. The main complications requiring hospitalization were perforation (n = 18, 1.9 ‰, 95 % CI 1.0-2.7) and bleeding (n = 31, 3.2 ‰, 95 % CI 2.1-4.4). Despite a significant increase in several risk factors for complication, the rate of AEs remained stable between gFOBT and FIT programs. Overall, we observed one death (1/27,000 colonoscopies) and three splenic injuries. Conclusions The harms of colonoscopy in a colorectal cancer screening program with FIT are more frequent than usually estimated. This study revealed six AEs requiring hospitalization > 24 hours (three bleeds, two perforations), one necessitating surgery, and 50 minor complications per 1000 colonoscopies.

16.
Med Pharm Rep ; 93(3): 301-305, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32832897

RESUMEN

We present an unusual case of an intra-abdominal collection which evidenced a rare etiology and raises diagnostic particularities. BACKGROUND: Fish bones ingestion is frequent, but seldom followed by complications. Those are often reported at specific sites. OBJECTIVES: This case report emphasizes the unusual presentation and site localization of a colonic perforation by a small fish bone, in the context of limited radiological accuracy at the diagnostic phase. CASE PRESENTATION: A 37 year old male was admitted to the gastroenterology ward with upper and left sided abdominal pain associated with fever and marked fatigue. His medical history was marked by a sleeve gastrectomy in 2010 for obesity. Abdominal signs and elevated acute inflammatory syndrome on blood tests were followed by computer tomography which revealed a pericolic mass near the left splenic flexure. The pain and fever increased in intensity, so a laparotomy was proposed. Intraoperatively, a tumor-like lesion was found and a resection with oncologic limits was performed. Microscopic examination of the specimen revealed a fish bone, but only after surgery did the patient confirm that he had eaten fish meal the week before. The post-operative period was uneventful. CONCLUSION: Fish bones remain some of the most frequently ingested alimentary foreign bodies; they may cause atypical clinical presentations, frequently omitted by the patients themselves if symptoms appear delayed. They could also lead to possible high-risk complications which need to be addressed by surgeons.

17.
Endoscopy ; 52(12): 1111-1115, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-32557489

RESUMEN

BACKGROUND: The SARS-CoV-2 pandemic has majorly affected medical activity around the world. We sought to measure the impact of the COVID-19 pandemic on gastrointestinal (GI) endoscopy activity in France. METHODS: We performed a web-based survey, including 35 questions on the responders and their endoscopic practice, from 23 March to 27 March 2020, sent to the 3300 French gastroenterologists practicing endoscopy. RESULTS: 694 GI endoscopists (21 %) provided analyzable data; of these, 29.4 % (204/694) were involved in the management of COVID-19 patients outside the endoscopy department. During the study period, 98.7 % (685/694) of endoscopists had had to cancel procedures. There were 89 gastroenterologists (12.8 %) who reported symptoms compatible with COVID-19 infection, and a positive PCR test was recorded in 12/197 (6.1 %) vs. 3/497 (0.6 %) endoscopists in the high vs. low prevalence areas, respectively (P < 0.001). CONCLUSIONS: The COVID-19 pandemic led to a major reduction in the volume of GI endoscopies performed in France in March 2020. The prolonged limited access to GI endoscopy could lead to a delay in the management of patients with GI cancers.


Asunto(s)
COVID-19/epidemiología , COVID-19/transmisión , Endoscopía Gastrointestinal/estadística & datos numéricos , Gastroenterología/estadística & datos numéricos , Departamentos de Hospitales/estadística & datos numéricos , Exposición Profesional , COVID-19/diagnóstico , COVID-19/prevención & control , Femenino , Francia/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Pandemias , Equipo de Protección Personal/provisión & distribución , Prevalencia , SARS-CoV-2 , Encuestas y Cuestionarios
18.
Soins ; 64(835): 40-42, 2019 May.
Artículo en Francés | MEDLINE | ID: mdl-31079787

RESUMEN

ADVANCED PRACTICE NURSES, THE PATIENTS' PERSPECTIVE: The recognition of advanced nursing practice is being met with great optimisim among patients. The care relationship will be enhanced by the creation of different partnerships between health professionals, patients and carers, which will ensure a better quality of initial and follow-up care. The patient will now be able to rely on the advanced practice nurse to guide them along a more global healthcare pathway. As a result, the care and support relationship will feel more human.


Asunto(s)
Enfermería de Práctica Avanzada , Satisfacción del Paciente , Humanos
19.
Expert Rev Pharmacoecon Outcomes Res ; 19(5): 601-608, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30739558

RESUMEN

Objectives: This study compared the cost and quality of life (QoL) of 407 advanced colorectal cancer patients, randomly assigned to receive LV5FU2 followed by FOLFOX6 (sequential strategy) or FOLFOX6 followed by FOLFIRI (combination strategy). Methods: Costs were compared from the French health insurance perspective, until the end of the second line of treatment. Consumed resources, collected during the trial, included medicines, hospitalizations, examinations, and transportation. Valuations were made using 2009 and 2016 tariffs. QoL was assessed using the QLQ-C30 questionnaire and clinically significant variations were searched. Results: In 2009, the mean cost per patient was significantly lower for the sequential strategy compared to the combination strategy (18,061€ and 23,119€, p = 0.001). In 2016, the difference was no longer significant (16,876€ and 18,090€, p = 0.41) because oxaliplatin and irinotecan became generics. The QoL analysis (292 patients) showed that there was significantly less improvement of global health status in the sequential strategy than in the combination strategy (29% and 42%; p = 0.02) during first-line therapy. No significant differences were observed for emotional functioning (p = 0.45) and physical functioning (p = 0.07) or during second-line therapy. Conclusion: The choice to treat patients with advanced colorectal cancer using one or the other strategy cannot be based on costs or QoL.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Neoplasias Colorrectales/tratamiento farmacológico , Calidad de Vida , Adulto , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/economía , Camptotecina/administración & dosificación , Camptotecina/análogos & derivados , Camptotecina/economía , Neoplasias Colorrectales/economía , Neoplasias Colorrectales/patología , Costos de los Medicamentos , Femenino , Fluorouracilo/administración & dosificación , Fluorouracilo/economía , Francia , Estado de Salud , Humanos , Leucovorina/administración & dosificación , Leucovorina/economía , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Compuestos Organoplatinos/administración & dosificación , Compuestos Organoplatinos/economía , Estudios Prospectivos , Encuestas y Cuestionarios
20.
Clin Res Hepatol Gastroenterol ; 43(3): 338-345, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30528512

RESUMEN

INTRODUCTION: In Europe, the number of cases of Campylobacter enteritis and their quinolone resistance is increasing. The aims of this work were to evaluate: (1) the hospital epidemiology of bacterial enteritis between 2010 and 2015. (2) The proportion of Campylobacter and Salmonella enteritis. (3) Resistance to quinolones in adult and paediatric populations. (4) To investigate possible regional epidemiological and bacteriological disparities. PATIENTS AND METHODS: This is a multicentric study carried out in 21 general hospitals (CHG) representing 14 French regions with a prospective collection of the results of coprocultures from 2010 to 2015 in adult and paediatric populations (children < 15 years old not exposed to quinolones). The epidemiological and bacteriological data were collected from software laboratory for positive stool cultures for Campylobacter and Salmonella. The results were compared year by year and by a period of 2 years. RESULTS: In adults, Campylobacter enteritis was each year significantly more frequent than Salmonella (P < 0.001), with a significant increase from 2010 to 2015 (P < 0.05). In children, there was also a significant and stable predominance of Campylobacter enteritis over the study period (P = 0.002). The quinolone resistance of Campylobacter was greater than 50% on the whole territory, with no North-South difference over the three periods studied. It increased significantly from 2012 to 2015 in adults (48% to 55%, P < 0.05) and in children (54% to 61%, P = 0.04). CONCLUSION: Our results confirm the increase in the prevalence of Campylobacter enteritis compared to Salmonella between 2010 and 2015. The quinolone resistance of Campylobacter is greater than 50% on the whole territory, stable between 2010 and 2015 in adults and significantly increased in children.


Asunto(s)
Infecciones por Campylobacter/epidemiología , Enteritis/epidemiología , Enteritis/microbiología , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Farmacorresistencia Bacteriana , Francia/epidemiología , Hospitales Generales , Humanos , Incidencia , Persona de Mediana Edad , Estudios Retrospectivos , Infecciones por Salmonella/epidemiología , Estaciones del Año , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...